-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Chronic Migraine
NCT07018713 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Lancaster, Los Angeles, Thousand Oaks
-
A Clinical Trial to Evaluate Efficacy and Safety of Xeomin® Injections for Preventing Episodic Migraine
NCT07018700 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Lancaster, Los Angeles, Thousand Oaks, Torrance
-
A Comprehensive Digital Care Program for Migraine Management
NCT07642414 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: San Francisco
-
A Long-Term Safety Study of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07674654 ·
Phase: Phase 3 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Colton, Culver City, Encino, Irvine
-
A Study of Oral Atogepant Tablets to Assess Adverse Events and Change in Disease Activity To Prevent Migraine in Participants Aged 12 to 17 Years
NCT06810505 ·
Phase: Phase 3 ·
Ages: 12 Years to 17 Years ·
Sex: All (male and female)
· California: Anaheim, Fresno, Long Beach, Oceanside
-
A Study to Assess the Adverse Events and Change in Disease Activity of Oral Atogepant Tablets in Pediatric Participants (6-17 Years of Age) With Episodic Migraine
NCT05711394 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· California: Anaheim, Long Beach, Oceanside, San Jose
-
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Apple Valley, Carlsbad, Encino, Fresno
-
A Study to Evaluate the Efficacy and Safety of Elismetrep (K-304) in the Acute Treatment of Migraine
NCT07645924 ·
Phase: Phase 3 ·
Ages: 18 Years to 75 Years ·
Sex: All (male and female)
· California: Colton, Culver City, Encino, Irvine
-
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
NCT06602479 ·
Phase: Phase 2 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· California: La Jolla, Los Angeles
-
A Study to Learn About the Safety of Taking an Additional Dose of the Medicine Rimegepant in Adults With Migraine
NCT07609914 ·
Phase: Phase 4 ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Canoga Park, Los Angeles
-
A Study to Learn About the Study Medicine Called Rimegepant in Women When Used for Intermittent Prevention of Menstrual Migraine
NCT06641466 ·
Phase: Phase 3 ·
Ages: 18 Years to 45 Years ·
Sex: Female
· California: Canoga Park, Colton, Walnut Creek
-
Analysis of Headache Chronification With Imaging, Deep Phenotyping, and Proteomics
NCT03231241 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Stanford
-
Clinical Trial of Endoscopically Guided Injection of Exparel (Bupivacaine) for the Treatment of Craniofacial Pain
NCT04930887 ·
Phase: Phase 2 ·
Ages: 18 Years to 80 Years ·
Sex: All (male and female)
· California: Stanford
-
Comparative Effectiveness of Migraine Preventive Medications: The APT Comparison Study
NCT06972056 ·
Phase: Phase 4 ·
Ages: 18 Years to 70 Years ·
Sex: All (male and female)
· California: Los Angeles, Palm Springs, Pomona
-
Efficacy and Safety Study of Rimegepant for the Preventative Treatment of Migraine in Pediatric Subjects
NCT05156398 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· California: Hawthorne, La Mesa
-
Emgality for Migraine in Breastmilk
NCT06085144 ·
Phase: Not specified ·
Ages: 18 Years to 45 Years ·
Sex: Female
· California: San Francisco
-
Long-term Safety Study of Rimegepant in Pediatric Subjects for the Acute Treatment of Migraine
NCT04743141 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· California: Anaheim, Culver City, Fresno, La Jolla
-
MMA Embolization for Refractory Chronic Migraine
NCT06735833 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Walnut Creek
-
Qudexy XR for the Prevention of Migraine in Children 6 to 11 Years Old
NCT04748601 ·
Phase: Phase 4 ·
Ages: 6 Years to 11 Years ·
Sex: All (male and female)
· California: La Jolla
-
Randomized Study in Children and Adolescents With Migraine: Acute Treatment
NCT04649242 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· California: Anaheim, Costa Mesa, Culver City, Fountain Valley
-
Responding With Evidence and Access for Childhood Headaches
NCT05889624 ·
Phase: Not applicable (e.g. observational or device study) ·
Ages: 10 Years to 17 Years ·
Sex: All (male and female)
· California: San Francisco
-
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
NCT07646613 ·
Phase: Phase 2 ·
Ages: 18 Years to 65 Years ·
Sex: All (male and female)
· California: Walnut Creek
-
Study of EVO756 in Adults With Migraine
NCT07616128 ·
Phase: Phase 2 ·
Ages: 18 Years to 64 Years ·
Sex: All (male and female)
· California: Buena Park, Fresno, Los Angeles, Walnut Creek
-
Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)
NCT05125302 ·
Phase: Phase 3 ·
Ages: 6 Years to 17 Years ·
Sex: All (male and female)
· California: Anaheim, Fresno, La Palma, Long Beach
-
Study to Assess the Real-World Effectiveness of Ubrogepant in Adult Participants When Treating During the Prodrome Phase of Migraine Attacks
NCT07310290 ·
Phase: Not specified ·
Ages: 18 Years and older ·
Sex: All (male and female)
· California: Aliso Viejo
-
Treatment of Meniere's Disease With Migraine Medications
NCT05582837 ·
Phase: Phase 4 ·
Ages: 25 Years to 85 Years ·
Sex: All (male and female)
· California: Orange